Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion is developing novel vaccines using their proprietary AI platform, AI-Immunology, which decodes the human immune system to target cancer and infectious diseases. The company's strong focus on personalized treatment options, with 15 shared ERV antigens across 95% of AML patients in their Phase 1 trial, showcases their potential in the market. With sufficient funding into 2H27, the company plans to pivot into autoimmune disease therapies, with their AI-Immunology model set to select 2-3 lead indications in 1H26. This strategic move could positively impact their licensing strategy and further drive their growth in the future.

Bears say

Evaxion is a clinical-stage TechBio company that is facing several potential risks, including potential technology and clinical issues, as well as competition in the market. Despite presenting strong data, the company is still in the early stages of developing its pipeline, and there are currently no approved products. Its financials show a strong balance sheet, but with multiple clinical candidates in different disease areas, it may be difficult to fully capitalize on the potential value of each candidate. Overall, the company's outlook is dependent on its ability to successfully progress its pipeline and secure partnerships and collaborations to drive future revenue and growth.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.